Clinical trial
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone…
NCT00286793 · Ascenta Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00286793 |
|---|---|
| Title | Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC |
| Official title | An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Ascenta Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | AT-101 |
| Enrollment | 76 |
| Start date | Feb 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Feb 6, 2006 |
| Last update posted | Jun 29, 2011 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: